Protocol Ledger

NCT06514794 · Phase II · RECRUITING

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Interventional Phase II clinical trial protocol NCT06514794 sponsored by Allotera Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-31 Enrollment: 125 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06514794
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)125 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06514794
Protocol FieldVerified Registry Value
NCT IdentifierNCT06514794
Consolidated Lead SponsorAllotera Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment125 participants (ESTIMATED)
Registered Start Date2025-01-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI